Celcuity Inc.
General ticker "CELC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Celcuity Inc. follows the US Stock Market performance with the rate: 48.5%.
Estimated limits based on current volatility of 2.8%: low 97.48$, high 103.15$
Factors to consider:
- Total employees count: 55 as of 2023
- Top business risk factors: Limited operating history, Labor/talent shortage/retention, Economic downturns and volatility, Cybersecurity threats, Regulatory and compliance
- Current price 549.8% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.04$, 16.29$]
- 2025-12-31 to 2026-12-31 estimated range: [5.45$, 12.92$]
Financial Metrics affecting the CELC estimates:
- Negative: with PPE of -4.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -16.61 <= 0.33
- Positive: 41.86 < Shareholder equity ratio, % of 47.17 <= 63.39
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 2.05 <= 3.41
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -12.55
- Positive: Inventory ratio change, % of 0 <= 0
Short-term CELC quotes
Long-term CELC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $39.39MM | $66.23MM | $113.27MM |
| Operating Income | $-39.39MM | $-66.23MM | $-113.27MM |
| Non-Operating Income | $-0.98MM | $2.45MM | $1.49MM |
| Interest Expense | $2.11MM | $5.33MM | $10.28MM |
| R&D Expense | $35.29MM | $60.59MM | $104.20MM |
| Income(Loss) | $-40.37MM | $-63.78MM | $-111.78MM |
| Profit(Loss)* | $-40.37MM | $-63.78MM | $-111.78MM |
| Stockholders Equity | $133.77MM | $139.77MM | $115.62MM |
| Assets | $175.70MM | $191.22MM | $245.12MM |
| Operating Cash Flow | $-36.01MM | $-53.81MM | $-83.47MM |
| Capital expenditure | $0.16MM | $0.10MM | $0.25MM |
| Investing Cash Flow | $-144.03MM | $-5.01MM | $-63.07MM |
| Financing Cash Flow | $120.33MM | $64.91MM | $138.39MM |
| Earnings Per Share** | $-2.62 | $-2.69 | $-2.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.